36.09
-1.05 (-2.83%)
| Previous Close | 37.14 |
| Open | 36.93 |
| Volume | 142,648 |
| Avg. Volume (3M) | 345,680 |
| Market Cap | 1,724,847,360 |
| Price / Book | 3.62 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -3.82 |
| Total Debt/Equity (MRQ) | 2.74% |
| Current Ratio (MRQ) | 31.01 |
| Operating Cash Flow (TTM) | -67.45 M |
| Levered Free Cash Flow (TTM) | -47.00 M |
| Return on Assets (TTM) | -22.89% |
| Return on Equity (TTM) | -33.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Rapport Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.80 |
|
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.28% |
| % Held by Institutions | 105.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Trv Gp V, Llc | 31 Dec 2025 | 7,135,233 |
| Arch Venture Management, Llc | 31 Dec 2025 | 3,728,738 |
| Cormorant Asset Management, Lp | 31 Dec 2025 | 3,027,521 |
| Johnson & Johnson | 31 Dec 2025 | 1,784,517 |
| Polar Capital Holdings Plc | 31 Dec 2025 | 1,004,728 |
| Trv Gp Vi, Llc | 31 Dec 2025 | 969,218 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 53.00 (BTIG, 46.86%) | Buy |
| Median | 49.50 (37.16%) | |
| Low | 46.00 (Wells Fargo, 27.46%) | Buy |
| Average | 49.50 (37.16%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 30.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 11 Mar 2026 | 53.00 (46.86%) | Buy | 30.54 |
| Wells Fargo | 11 Mar 2026 | 46.00 (27.46%) | Buy | 30.54 |
| 02 Feb 2026 | 43.00 (19.15%) | Buy | 27.75 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| YELESWARAM KRISHNASWAMY | - | 34.67 | -20,225 | -715,511 |
| Aggregate Net Quantity | -20,225 | |||
| Aggregate Net Value ($) | -715,511 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 34.67 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| YELESWARAM KRISHNASWAMY | Officer | 14 Apr 2026 | Automatic sell (-) | 10,200 | 36.15 | 368,730 |
| YELESWARAM KRISHNASWAMY | Officer | 13 Apr 2026 | Automatic sell (-) | 9,165 | 34.65 | 317,567 |
| YELESWARAM KRISHNASWAMY | Officer | 10 Apr 2026 | Automatic sell (-) | 500 | 34.17 | 17,085 |
| YELESWARAM KRISHNASWAMY | Officer | 08 Apr 2026 | Automatic sell (-) | 360 | 33.69 | 12,128 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |